ArticleBlood2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome.
Abstract readCase ReportsLetter
In one paragraph
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Epigenetics as a mechanism of lineage extinction and relapse of B-cell lymphoma treated with CD19 CAR T-cell therapy.Blood neoplasia · 2026Article
- Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.Biomarker research · 2026Article
- Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.Journal of hematopathology · 2025Article
- Innovative gene engineering strategies to address tumor antigen escape in cell therapy.Journal of translational medicine · 2025Review
- DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response.Blood cancer discovery · 2025Article
- Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.Methods and protocols · 2025Review
- Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2025Review
- Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.Bone marrow transplantation · 2025Review
- Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.Journal for immunotherapy of cancer · 2025Review
- Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy.Frontiers in pharmacology · 2025Review
- Transdifferentiation of Multiple Myeloma into Histiocytic Sarcoma: Case Report of a Highly Unusual Phenomenon.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy.Journal of hematopathology · 2024Article
- Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.Journal of biomedical science · 2024Review
- Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.Frontiers in oncology · 2024Review
- Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop.American journal of clinical pathology · 2023Article
- Review
- Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.Virchows Archiv : an international journal of pathology · 2022Article
- Born to survive: how cancer cells resist CAR T cell therapy.Journal of hematology & oncology · 2021Review
- Lineage Plasticity in Cancer: The Tale of a Skin-Walker.Cancers · 2021Review
- Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma WithFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Qian ZhangDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Elena J OrlandoNovartis Institute for Biomedical Research, Cambridge, MA.
Hong Y WangDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Agata M BoguszDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Xiaobin LiuDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Simon F LaceyFox Chase Cancer Center, Philadelphia, PA; and.
Honore T StrauserDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Selene Nunez-CruzDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Reza NejatiFox Chase Cancer Center, Philadelphia, PA; and.
Paul ZhangDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Sarah BrooksDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Christopher WattDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
J Joseph MelenhorstCenter for Cellular Immunotherapies and.
Carl H JuneDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Stephen J SchusterLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Mariusz A WasikDepartment of Pathology, University of Pennsylvania, Philadelphia, PA.
Funding
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase InhibitionR01CA228457 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NATH, KAVINDRA, WASIK, MARIUSZ A. · 2020 to 2024
$2.5MNCI NIH HHS R01 CA228457
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell TransdifferentiationAdenineAntineoplastic Combined Chemotherapy ProtocolsCellular ReprogrammingCombined Modality TherapyEpigenesis, GeneticEpigenomeGene RearrangementGenes, Immunoglobulin Heavy ChainHumansImmunotherapyLymph NodesLymphoma, Mantle-CellNeoplasms, Second PrimaryPiperidinesReceptors, Antigen, T-CellAdenineCTL019 chimeric antigen receptoribrutinibPiperidinesReceptors, Antigen, T-CellRituximab
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.